ロード中...

An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors

EGFR is an oncogene with a high frequency of activating mutations in nonsmall cell lung cancer (NSCLC). EGFR inhibitors have been FDA-approved for NSCLC and have shown efficacy in patients with certain EGFR mutations. However, only 9% to 26% of these patients achieve objective responses. In our stud...

詳細記述

保存先:
書誌詳細
出版年:Int J Cancer
主要な著者: Cheng, Chao, Zhao, Yanding, Schaafsma, Evelien, Weng, Yi-Lan, Amos, Christopher
フォーマット: Artigo
言語:Inglês
出版事項: 2020
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7880578/
https://ncbi.nlm.nih.gov/pubmed/32406930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33053
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!